VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 1 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2023. The put-call ratio across all filers is - and the average weighting 2.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2016 | $42,947,000 | -73.4% | 1,633,000 | +2.9% | 0.87% | -71.1% |
| Q4 2015 | $161,310,000 | -34.1% | 1,586,925 | +15.6% | 3.02% | -35.0% |
| Q3 2015 | $244,824,000 | -21.0% | 1,372,490 | -1.7% | 4.64% | -14.5% |
| Q2 2015 | $310,099,000 | +15.3% | 1,395,900 | +3.1% | 5.42% | +6.9% |
| Q1 2015 | $269,021,000 | +38.7% | 1,354,455 | -0.0% | 5.07% | +27.7% |
| Q4 2014 | $193,909,000 | +11.3% | 1,354,970 | +2.0% | 3.97% | -3.1% |
| Q3 2014 | $174,262,000 | +4.0% | 1,328,220 | 0.0% | 4.10% | +2.9% |
| Q2 2014 | $167,515,000 | -16.0% | 1,328,220 | -12.2% | 3.98% | -17.3% |
| Q1 2014 | $199,396,000 | +13.5% | 1,512,530 | +1.1% | 4.81% | +12.7% |
| Q4 2013 | $175,669,000 | +14.1% | 1,496,330 | +1.4% | 4.27% | +3.7% |
| Q3 2013 | $154,023,000 | +27.3% | 1,476,310 | +5.1% | 4.12% | +11.4% |
| Q2 2013 | $120,970,000 | – | 1,405,325 | – | 3.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |